TCGA-05-4403-01A-01R-1206-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 76
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- COAGULATION+0.490
- INTERFERON_ALPHA_RESPONSE+0.470
- COMPLEMENT+0.440
- PANCREAS_BETA_CELLS+0.440
- INFLAMMATORY_RESPONSE+0.410
- ESTROGEN_RESPONSE_LATE+0.390
- CHOLESTEROL_HOMEOSTASIS+0.380
- ADIPOGENESIS+0.370
- ESTROGEN_RESPONSE_EARLY+0.370
- INTERFERON_GAMMA_RESPONSE+0.370
Top 10 suppressed
- E2F_TARGETS-0.630
- G2M_CHECKPOINT-0.580
- MYC_TARGETS_V2-0.580
- MYC_TARGETS_V1-0.400
- MITOTIC_SPINDLE-0.330
- SPERMATOGENESIS-0.300
- UNFOLDED_PROTEIN_RESPONSE-0.270
- MTORC1_SIGNALING-0.230
- WNT_BETA_CATENIN_SIGNALING-0.160
- DNA_REPAIR-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
2 twins match this tumor's tissue · 8 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_FJZPQZ2C | pleomorphic xanthoastrocytoma(PXA) | — | 0.934 |
| 2 | BS_3G3KWY18 | low-grade glioma | — | 0.924 |
| 3 | BS_3W07B2TG | subependymal giant cell astrocytoma(SEGA) | — | 0.912 |
| 4 | BS_GWCRMKE6 | pilocytic astrocytoma | — | 0.900 |
| 5 | TCGA-67-3772-01A-01R-0946-07 | — | cohortA1 | 0.897 |
| 6 | BS_HC5M8JTC | low-grade glioma | — | 0.891 |
| 7 | BS_EFEZB0ZH | low-grade glioma | — | 0.889 |
| 8 | BS_YEQVW4ND | low-grade glioma | — | 0.889 |
| 9 | BS_M4TTKPNR | pilocytic astrocytoma | — | 0.886 |
| 10 | SRR27320696 | — | — | 0.885 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 39 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| COAGULATION | 0.490 | Binimetinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.470 | Inavolisib | — uncovered |
| COMPLEMENT | 0.440 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.440 | Cobimetinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.410 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.390 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.380 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.370 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.370 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.370 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.360 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.360 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.340 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.340 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.330 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.330 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.320 | Temsirolimus | — uncovered |
| IL2_STAT5_SIGNALING | 0.320 | Idelalisib | — uncovered |
| APOPTOSIS | 0.310 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.300 | Inavolisib | — uncovered |